Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis

• Main Authors: Kento Inada, Shun Kaneko, Masayuki Kurosaki, Koji Yamashita, Sakura Kirino, Leona Osawa, Yuka Hayakawa, Shuhei Sekiguchi, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Jun Itakura, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Ryuichi Okamoto, Namiki Izumi
• Format: Article
• Language: English
• Published: Wiley 2021-09-01
• Series: JGH Open
• Subjects: de novo hepatitis; hepatitis B virus reactivation; tenofovir alafenamide
• Online Access: https://doi.org/10.1002/jgh3.12636

Abstract Background and Aim Administration of tenofovir alafenamide (TAF) as prevention or treatment of hepatitis B virus (HBV) reactivation is not well known. The aim of this study is to reveal the efficacy and safety of TAF against HBV reactivation. Methods Entecavir (ETV) and TAF were given to 66 and 11 patients, respectively, as prophylaxis against or treatment of HBV reactivation during chemotherapy or immune suppression therapy from January 2010 to June 2020. The antiviral effects and safety were assessed. Results At week 24, the antiviral effects on patients receiving ETV and TAF were similar in terms of reduction of HBV DNA (−2.83 ± 1.45log IU/mL vs −3.05 ± 2.47log IU/mL; P = 0.857) and achieving undetectable levels of HBV DNA (78.8 vs 90.9%; P = 0.681). There was no significant difference in the decrease in the estimated glomerular filtration rate (eGFR) between the two groups (−0.62 ± 11.2 mL/min/1.73 m2 vs −3.67 ± 13.2 mL/min/1.73 m2; P = 0.291). Conclusion TAF is safe and effective against HBV reactivation.